The Online Investor

Slideshow Mergers & Acquisitions

By The Online Investor Staff, updated Sat., Sep. 19, 8:26 AM

Slide #66. Sorrento Therapeutics, Inc. SmartPharm Therapeutics, Inc.

Acquirer: Sorrento Therapeutics, Inc. (NASDAQ:SRNE)
Acquiree: SmartPharm Therapeutics, Inc.
Details: Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") and SmartPharm Therapeutics, Inc. ("SmartPharm") announced today that Sorrento has completed the acquisition of SmartPharm, a gene-encoded protein therapeutics company developing non-viral DNA and RNA gene delivery platforms for COVID-19 and rare diseases with broad potential application in enhancing any antibody-centric therapeutics.

Sorrento Therapeutics is a clinical stage and commercial biopharma company focused on delivering therapies to patients and their families. Co. has two segments: The Sorrento Therapeutics segment, which is organized around its Immune-Oncology therapeutic area, using its proprietary G-MAB™ antibody library and targeted delivery modalities to generate the next generation of cancer therapeutics. These modalities include proprietary chimeric antigen receptor T-cell therapy, dimeric antigen receptor T-cell therapy, antibody drug conjugates as well as bispecific antibody approaches. The Scilex segment is mainly organized around Co.'s non-opioid pain management operations.

SRNE SEC Filing Email Alerts Service

Open the SRNE Page at The Online Investor »

Company Name: 
Sorrento Therapeutics Inc
Number of ETFs Holding SRNE: 
Total Market Value Held by ETFs: 
Total Market Capitalization: 
% of Market Cap. Held by ETFs: 

Open the SRNE Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes

Strong Buy (4.00 out of 4)
82nd percentile
(ranked higher than approx. 82% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Mergers & Acquisitions Page |

Copyright © 1998 - 2020, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.